Considering that loss of DRAK1 expression activates the TRAF6-mediated inflammatory response in metastatic cervical cancer cells reported in our previous study, we examined whether aberrant expression of DRAK1 is related to paclitaxel resistance, which results in tumor progression of cervical cancer cells. The gene discussed is STK17A; the disease is cervical cancer.